RESEARCH PROFILE
CJC-1295 NO DAC
Modified GRF 1-29 • Short Acting GHRH Analog
CJC-1295 No DAC, commonly referred to as Modified GRF 1-29, is a short acting synthetic analog of growth hormone releasing hormone designed to stimulate signaling through the GHRH receptor and promote pulsatile growth hormone release.
Unlike longer acting CJC-1295 formulations containing a Drug Affinity Complex, the No DAC form is designed for relatively brief activity rather than prolonged exposure.
INVESTIGATIONAL • NOT FDA APPROVED • LIMITED DIRECT HUMAN EVIDENCE
CJC-1295 NO DAC AT A GLANCE
Category
Growth hormone releasing hormone analog
Alternate Names
Modified GRF 1-29 • Mod GRF 1-29
Primary Target
GHRH receptor
Primary Research Pathway
Growth hormone • IGF-1 axis
Activity Profile
Short acting • Pulsatile GH signaling
Regulatory Status
Not FDA approved
IMPORTANT DISTINCTION
CJC-1295 No DAC should not be treated as interchangeable with CJC-1295 with DAC.
The No DAC variant is short acting, while the DAC modification used in other CJC-1295 research substantially prolongs exposure through albumin binding.
Your Project source estimates the No DAC variant's activity at roughly 30 minutes, whereas DAC-containing CJC-1295 has a substantially longer pharmacokinetic profile.
That difference changes how the compounds behave biologically and means clinical findings from DAC-containing CJC-1295 cannot automatically be attributed to CJC-1295 No DAC.
WHAT IS CJC-1295 NO DAC?
CJC-1295 No DAC is a synthetic peptide designed to mimic signaling from the body's natural growth hormone releasing hormone, or GHRH.
GHRH is produced by the hypothalamus and acts on the pituitary gland, where it stimulates release of growth hormone.
CJC-1295 No DAC is commonly referred to as Modified GRF 1-29 because it is based on the biologically active 29 amino acid region of GHRH but incorporates amino acid substitutions intended to increase resistance to enzymatic degradation.
The defining characteristic of the No DAC variant is its short duration of action.
Rather than producing the prolonged exposure associated with DAC-containing CJC-1295, Modified GRF 1-29 is intended to produce relatively brief GHRH receptor stimulation.
This is why CJC-1295 No DAC is generally discussed as a pulsatile GH-axis research compound rather than a compound intended to maintain continuously elevated growth hormone concentrations.
MECHANISM OF ACTION
CJC-1295 No DAC acts through the physiological signaling pathway responsible for stimulating pituitary growth hormone release.
GHRH RECEPTOR
CJC-1295 No DAC acts as a GHRH receptor agonist.
After GHRH receptor activation at the pituitary, somatotroph cells are stimulated to release stored growth hormone.
The compound therefore acts upstream of growth hormone rather than functioning as exogenous growth hormone itself.
GROWTH HORMONE PULSE
Because the No DAC variant is short acting, its biological rationale centers on producing a relatively brief growth hormone pulse.
This differs from the prolonged GH and IGF-1 elevations observed with longer acting DAC-containing CJC-1295.
IGF-1 SIGNALING
Growth hormone released from the pituitary subsequently signals tissues including the liver.
One downstream consequence of GH signaling is production of insulin-like growth factor 1, or IGF-1.
IGF-1 is therefore frequently used in GH-axis research as a downstream marker of repeated growth hormone stimulation.
PHYSIOLOGICAL FEEDBACK REMAINS RELEVANT
The GH axis remains subject to endogenous regulatory mechanisms, including hypothalamic and pituitary feedback.
This is one reason short acting GHRH analogs are studied differently from direct administration of recombinant growth hormone.
DISTINCT FROM GHRELIN RECEPTOR AGONISTS
CJC-1295 No DAC stimulates the GHRH receptor.
Compounds such as Ipamorelin stimulate growth hormone release through the ghrelin receptor, a different signaling pathway.
The two mechanisms should therefore not be described as identical even though both can influence pituitary growth hormone release.
WHAT THE RESEARCH SHOWS
DIRECT HUMAN EVIDENCE IS LIMITED
This is the most important evidence qualification for this profile.
Your Project source states:
Human evidence for the No DAC variant specifically is limited.
There is not a large clinical trial program establishing CJC-1295 No DAC as an effective treatment for body composition, muscle growth, fat loss, sleep, recovery, anti-aging, or other commonly marketed outcomes.
PARENT CJC-1295 HUMAN RESEARCH
Published human research has evaluated CJC-1295 formulations with longer acting pharmacology, including DAC-containing CJC-1295.
In a Phase 1 study reported by Teichman and colleagues, administration of CJC-1295 in healthy adults produced increases in growth hormone and IGF-1.
The investigators reported prolonged GH stimulation and sustained IGF-1 elevation following administration.
This provides evidence that the broader CJC-1295 family can activate the human GH/IGF-1 axis.
It does not establish the same pharmacokinetics, magnitude of effect, duration, or clinical outcomes for CJC-1295 No DAC.
PULSATILE GH SECRETION
Research by Ionescu and Frohman examining CJC-1295 reported that pulsatile growth hormone secretion could remain present despite sustained stimulation of the GH axis.
This finding is relevant to understanding the physiology of GHRH analog signaling.
Again, this research involved parent CJC-1295 and should not be presented as a direct clinical trial of Modified GRF 1-29.
PRECLINICAL RESEARCH
Preclinical research involving CJC-1295 and related GHRH analogs has demonstrated stimulation of the GH/IGF-1 pathway.
Animal research has also investigated effects on growth and body composition.
These studies help establish biological plausibility but cannot establish clinical benefits for CJC-1295 No DAC in humans.
WHAT THE RESEARCH SUPPORTS
The evidence supports the underlying biological pathway:
GHRH receptor activation → pituitary GH release → downstream IGF-1 signaling
There is also human evidence that related CJC-1295 compounds can meaningfully influence the GH/IGF-1 axis.
WHAT HAS NOT BEEN ESTABLISHED
Direct clinical evidence has not established CJC-1295 No DAC as an FDA approved treatment for:
Muscle growth
Fat loss
Athletic performance
Recovery
Sleep enhancement
Anti-aging
Longevity
Body recomposition
IMPORTANT EVIDENCE LIMITATION
The commonly discussed research protocols for CJC-1295 No DAC are largely extrapolated from:
Parent CJC-1295 research
GHRH physiology
Related GHRH analog research
Community research practices
They should not be represented as clinically validated No DAC treatment protocols.
SAFETY & RESEARCH CONSIDERATIONS
The absence of large, long-term clinical trials specifically evaluating CJC-1295 No DAC creates significant uncertainty regarding its complete safety profile.
COMMONLY DISCUSSED EFFECTS
Your Project profile identifies commonly reported effects associated with short acting CJC-1295 research including:
Mild flushing or warmth
Headache
Injection site redness or irritation
Mild fluid retention or puffiness
Tingling or numbness of the hands
The Project source notes that some effects appear more noticeable with higher individual exposures.
GLUCOSE & INSULIN SIGNALING
Growth hormone can influence glucose metabolism and insulin sensitivity.
For that reason, alterations in fasting glucose, glycemic control, or insulin sensitivity are biologically relevant considerations when researching compounds that stimulate the GH axis.
People with significant glucose dysregulation or uncontrolled diabetes represent an important precautionary population.
FLUID RETENTION
GH-axis stimulation may contribute to fluid retention.
Persistent or substantial edema should not simply be assumed to be an expected research effect because swelling can have other medical causes.
IGF-1 & CELL GROWTH
Repeated GH stimulation may increase downstream IGF-1 signaling.
Because GH and IGF-1 participate in cellular growth pathways, your Project source treats active or recent cancer history as an important precaution/exclusion consideration.
That is a theoretical and biological safety concern rather than proof that CJC-1295 No DAC causes cancer.
CARDIOVASCULAR UNCERTAINTY
Your Project source also notes a historical CJC-1295 clinical development event involving a participant death during a Phase 2 study of the DAC-containing formulation.
Investigators reportedly considered the cardiovascular event unrelated to the compound, but development of that program was discontinued.
That event involved CJC-1295 with DAC, not CJC-1295 No DAC, and should not be misrepresented as a documented No DAC adverse event.
LONG TERM DATA
There are no robust multi-year human safety data specifically establishing the long-term safety of CJC-1295 No DAC.
Claims that the compound is inherently safer simply because it is short acting therefore go beyond the available evidence.
REGULATORY CONTEXT
CJC-1295 NO DAC IS NOT FDA APPROVED
CJC-1295 No DAC, also known as Modified GRF 1-29, is not an FDA approved drug.
There is no FDA approved therapeutic indication specifically for CJC-1295 No DAC.
Your Project profile also identifies:
No active FDA approved human-use indication
No established FDA approved dosing regimen
No FDA approved labeling establishing safety or effectiveness
RESEARCH STATUS
CJC-1295 No DAC is commonly encountered in research settings, but the presence of a compound in the research marketplace does not establish regulatory approval, clinical effectiveness, manufacturing quality, or medical suitability.
RELATED COMPOUNDS ARE NOT INTERCHANGEABLE
Regulatory or clinical information concerning:
CJC-1295 with DAC
Sermorelin
Tesamorelin
Ipamorelin
Recombinant human growth hormone
should not be transferred automatically to CJC-1295 No DAC.
These compounds differ in structure, pharmacology, regulatory history, receptor signaling, or duration of action.
SPORT & ANTI-DOPING
Growth hormone releasing factors and related substances fall within prohibited categories under the World Anti-Doping Agency Prohibited List.
Competitive athletes subject to WADA or comparable anti-doping rules should therefore not assume that a research designation makes CJC-1295 No DAC permissible.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
CJC-1295 NO DAC
LOT SPECIFIC ANALYTICAL DOCUMENTATION
Analytical documentation is displayed only when Croix has a corresponding laboratory report that can be matched to the specific product and lot.
No matching standalone CJC-1295 No DAC COA is currently displayed.
IMPORTANT COA LIMITATION
When analytical documentation becomes available, results should apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix's documentation standard requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before a COA is represented as supporting a product. Croix_Peptides_Brand_Pricing_Op…
A passing COA also does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Teichman SL, Neale A, Lawrence B, et al.
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults.
Journal of Clinical Endocrinology & Metabolism. 2006.
Human research evaluating the effects of parent CJC-1295 on growth hormone and IGF-1 signaling.
Ionescu M, Frohman LA.
Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295.
Journal of Clinical Endocrinology & Metabolism. 2006.
Research examining growth hormone pulsatility during CJC-1295 stimulation.
Alba M, Fintini D, Sagazio A, et al.
Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse.
American Journal of Physiology Endocrinology and Metabolism. 2006.
Preclinical research involving CJC-1295 and the GH axis.
Jette L, Leger R, Thibaudeau K, et al.
Research describing the albumin-binding chemistry and pharmacology underlying long-acting CJC-1295.
This work is particularly useful for understanding why DAC-containing CJC-1295 differs pharmacokinetically from the No DAC variant.
Henninge J, Pepaj M, Hullstein I, Hemmersbach P.
Research identifying CJC-1295 in an unapproved pharmaceutical preparation.
World Anti-Doping Agency
Prohibited List — Peptide Hormones, Growth Factors, Related Substances and Mimetics.
EVIDENCE NOTE
Several of the foundational CJC-1295 studies above concern longer acting or DAC-containing CJC-1295 rather than Modified GRF 1-29 specifically.
They are included to document the scientific development of the CJC-1295 family and GH-axis pharmacology, not as direct proof of clinical efficacy or safety for CJC-1295 No DAC.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish CJC-1295 No DAC as safe or effective for personal use.
CJC-1295 No DAC, also known as Modified GRF 1-29, is not FDA approved.
Direct human clinical evidence specifically evaluating the No DAC variant is limited. Research involving longer acting or DAC-containing CJC-1295 should not be interpreted as establishing equivalent pharmacokinetics, safety, efficacy, or clinical outcomes for CJC-1295 No DAC.
Claims involving muscle growth, fat loss, recovery, sleep, anti-aging, or other clinical outcomes exceed what has been established specifically for the No DAC variant in controlled human trials.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.